Biogen is one of the oldest independent biotechnology companies active in the field of neuroscience. Today, the company has a leading drug portfolio for the treatment of multiple sclerosis and the first approved therapy for spinal muscular atrophy. The company also markets biosimilars and is focused on advancing one of the most diverse pipelines in neuroscience.